Impax Laboratories Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Impax Laboratories Inc (Impax) develops, manufactures and markets generic and branded pharmaceuticals. It offers solid dose and alternative dosage form generic drugs in a broad range of therapeutic areas; and proprietary branded pharmaceutical products for the treatment of central nervous system (CNS) disorders and other select specialties. Impax develops several controlled-release delivery technologies which can be utilized with a variety of oral dosage forms and drugs. It has manufacturing facilities in Hayward, California; Middlesex, New Jersey; and in Taiwan. The company sells its products directly to wholesalers and large retail drug chains and through unrelated third-party pharmaceutical entities. Impax is headquartered in Hayward, California, the US.

Impax Laboratories Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

It derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Impax Laboratories Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Impax Labs Acquires Generic Products from Teva Pharma and Allergan for USD586 Million 13
Impax Labs Acquires Two Generic Products from Actavis 15
Amedra Pharmaceuticals Acquires Mebendazole Tablet Product from Teva Pharmaceutical 16
Partnerships 17
Impax Labs Enters Into Co-Development Agreement With Perrigo 17
Impax Labs Enters Into Development And Distribution Agreement With Tolmar 18
IMPAX Lab Enters Into Co-Development Agreement With TOLMAR 19
Merger 20
Amneal Merges with Impax 20
Licensing Agreements 22
Impax Labs Enters Into Licensing Agreement With Durect For Eladur 22
Impax Pharma Amends Licensing Agreement with AstraZeneca for Zomig 24
Debt Offering 26
Impax Labs Raises USD600 Million in Private Placement of 2% Notes Due 2022 26
Asset Transactions 28
ANI Pharma to Acquire Manufacturing Equipment from Amneal Pharma and Impax Labs 28
ANI Pharma to Acquire Generic Products from Amneal Pharma and Impax Labs 29
Bora Pharma to Acquire Manufacturing Facility from Impax Labs for USD18.5 Million 31
Turing Pharma Acquires Daraprim Marketing Rights in US from Impax Lab for USD55 Million 32
Acquisition 33
Impax Laboratories Sells CorePharma to Group Investors 33
Impax Acquires Lineage Therapeutics, Amedra Pharma and CorePharma for USD700 Million 34
Impax Laboratories Inc - Key Competitors 36
Impax Laboratories Inc - Key Employees 37
Impax Laboratories Inc - Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 40
Financial Announcements 40
Mar 01, 2018: Impax Reports Fourth Quarter and Full Year 2017 Results 40
Nov 09, 2017: Impax Reports Third Quarter 2017 Results 43
Aug 09, 2017: Impax Reports Solid Second Quarter 2017 Results with Total Revenues Increasing 17% to $202 Million 45
May 10, 2017: Impax Reports First Quarter 2017 Financial Results 47
Mar 01, 2017: Impax Reports Fourth Quarter and Full Year 2016 Financial Results 50
Corporate Communications 53
Nov 08, 2017: Impax Laboratories Mourns the Passing of Board Member Richard A. Bierly 53
Mar 27, 2017: Impax Board of Directors Appoints Paul M. Bisaro President and CEO 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55

List Of Tables


Impax Laboratories Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Impax Laboratories Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Impax Laboratories Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Impax Labs Acquires Generic Products from Teva Pharma and Allergan for USD586 Million 13
Impax Labs Acquires Two Generic Products from Actavis 15
Amedra Pharmaceuticals Acquires Mebendazole Tablet Product from Teva Pharmaceutical 16
Impax Labs Enters Into Co-Development Agreement With Perrigo 17
Impax Labs Enters Into Development And Distribution Agreement With Tolmar 18
IMPAX Lab Enters Into Co-Development Agreement With TOLMAR 19
Amneal Merges with Impax 20
Impax Labs Enters Into Licensing Agreement With Durect For Eladur 22
Impax Pharma Amends Licensing Agreement with AstraZeneca for Zomig 24
Impax Labs Raises USD600 Million in Private Placement of 2% Notes Due 2022 26
ANI Pharma to Acquire Manufacturing Equipment from Amneal Pharma and Impax Labs 28
ANI Pharma to Acquire Generic Products from Amneal Pharma and Impax Labs 29
Bora Pharma to Acquire Manufacturing Facility from Impax Labs for USD18.5 Million 31
Turing Pharma Acquires Daraprim Marketing Rights in US from Impax Lab for USD55 Million 32
Impax Laboratories Sells CorePharma to Group Investors 33
Impax Acquires Lineage Therapeutics, Amedra Pharma and CorePharma for USD700 Million 34
Impax Laboratories Inc, Key Competitors 36
Impax Laboratories Inc, Key Employees 37
Impax Laboratories Inc, Other Locations 38
Impax Laboratories Inc, Subsidiaries 38

List Of Figures


Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Impax Laboratories Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Impax Laboratories Inc (Impax) develops, manufactures and markets generic and branded pharmaceuticals. It offers solid dose and alternative dosage form generic drugs in a broad range of therapeutic areas; and

USD 250 View Report

Impax Laboratories Inc Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Impax Laboratories Inc Company Profile is a detailed strategic and analytical report on Impax Laboratories Inc. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200 View Report

ARTANN Laboratories Inc - Product Pipeline Analysis, 2019 Update

Artann Laboratories Inc (Artann) is a medical device company that provides ultrasound solutions. The company offers early stage development and validation of original technologies and devices. Its products include tissue

USD 750 View Report

Silicon Laboratories Inc (SLAB) - Financial and Strategic SWOT Analysis Review

Silicon Laboratories Inc (SLAB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled to

USD 125 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available